Form 4: Cryo-Cell Co-CEO Portnoy Boosts Stake with 39,179 Shares
Insider Transaction Report
Cryo-Cell International's Chairman and Co-CEO, David Portnoy, increased his beneficial ownership by purchasing 39,179 shares of common stock across multiple transactions in late August 2025.
Summary
- David Portnoy, Chairman and Co-CEO of Cryo-Cell International Inc. (CCEL), acquired a total of 39,179 shares of common stock through multiple purchases between August 25 and August 27, 2025.
- These purchases were executed through his 401K and IRA accounts, demonstrating personal investment in the company.
- The shares were acquired at weighted average prices ranging from $4.41 to $4.65 per share.
- Following these transactions, Portnoy's indirect beneficial ownership through his 401K increased to 164,182 shares and through his IRA to 247,757 shares.
- His total beneficial ownership includes 804,742 shares held directly, and additional indirect holdings through his spouse, various LLCs, corporations, and as custodian for his children.
- Portnoy also holds several stock options with exercise prices ranging from $4.30 to $12.27, with various vesting schedules, including one that vests immediately if the stock price reaches $25.00 per share.
Sentiment
Score: 8
Explanation: The significant insider buying by the Chairman and Co-CEO, David Portnoy, indicates strong confidence in the company's future performance and valuation. This is generally a positive signal for investors, suggesting management believes the stock is undervalued.
Positives
- Significant insider buying by a key executive (Chairman and Co-CEO) indicates strong confidence in the company's future prospects and current valuation.
- The acquisition of 39,179 shares at prices between $4.41 and $4.65 demonstrates a substantial personal investment in the company's performance.
- Purchases made through personal retirement accounts (401K and IRA) suggest a long-term investment horizon and belief in sustained growth.
Future Outlook
The filing does not contain explicit forward-looking statements or guidance beyond the vesting conditions for certain stock options, which are tied to future stock price performance or specific dates.
Industry Context
This Form 4 filing, detailing insider stock purchases, does not provide specific industry context. However, insider buying in the stem cell banking sector could signal management's belief in the company's competitive position or future growth within the industry.
Related Party Transactions
- Indirect beneficial ownership through Mayim Limited Partnership, where David Portnoy may be deemed the beneficial owner as the managing member and owner of Mayim Management, LLC, which is the general partner of Mayim Management Limited Partnership, which is the general partner of Mayim Investment Limited Partnership.
- Indirect beneficial ownership through uTIPu, Inc., where David Portnoy may be deemed the beneficial owner as the Chairman of the Board and Secretary.
- Indirect beneficial ownership through Partner Community, where David Portnoy may be deemed the beneficial owner as the Chairman of the Board and Secretary.
Stakeholder Impact
- Shareholders: The insider buying could instill greater confidence in the company's prospects, potentially leading to increased investor interest and a positive impact on share price.
- Management/Employees: Demonstrates strong alignment between top leadership and shareholder interests, potentially boosting morale and commitment.
Key Dates
| Date | Description |
|---|---|
| 08/30/2019 | Date exercisable for stock option with exercise price $7.53 and expiration date 08/30/2029. |
| 12/20/2019 | Date exercisable for stock option with exercise price $7.28 and expiration date 12/20/2029. |
| 12/22/2021 | Date exercisable for stock option with exercise price $12.27 and expiration date 12/22/2028. Options vest immediately if the Company's common stock reaches $25.00 per share during the seven-year option term. |
| 12/23/2022 | Date exercisable for stock option with exercise price $4.30 and expiration date 12/23/2027. |
| 01/03/2023 | Date exercisable for stock option with exercise price $4.77 and expiration date 01/03/2028. Vesting schedule: 8,750 options vest upon issuance, 8,749 options vest on 1/2/2024, 21,000 options vest on 1/2/2025, and 11,501 options vest on 1/2/2026. |
| 12/22/2023 | Date exercisable for stock option with exercise price $6.47 and expiration date 12/22/2028. Vesting schedule: 1/3 upon issuance, 1/3 on December 22, 2024, and 1/3 on December 22, 2025. |
| 01/02/2024 | Vesting date for 8,749 stock options with an exercise price of $4.77. |
| 12/22/2024 | Vesting date for 1/3 of stock options with an exercise price of $6.47. |
| 01/21/2025 | Date exercisable for stock option with exercise price $8.08 and expiration date 01/21/2030. Vesting schedule: 1/3 upon issuance, 1/3 on January 21, 2026, and 1/3 on January 21, 2027. |
| 01/02/2025 | Vesting date for 21,000 stock options with an exercise price of $4.77. |
| 08/25/2025 | David Portnoy purchased 4,500 shares at $4.65 (401K), 5,000 shares at $4.65 (401K), and 4,500 shares at $4.53 (IRA). |
| 08/26/2025 | David Portnoy purchased 11,101 shares at $4.44 (401K). |
| 08/27/2025 | David Portnoy purchased 7,860 shares at $4.42 (401K) and 6,218 shares at $4.44 (IRA). Signature date of the filing. |
| 12/22/2025 | Vesting date for 1/3 of stock options with an exercise price of $6.47. |
| 01/02/2026 | Vesting date for 11,501 stock options with an exercise price of $4.77. |
| 01/21/2026 | Vesting date for 1/3 of stock options with an exercise price of $8.08. |
| 01/21/2027 | Vesting date for 1/3 of stock options with an exercise price of $8.08. |
| 12/23/2027 | Expiration date for stock option with exercise price $4.30. |
| 01/03/2028 | Expiration date for stock option with exercise price $4.77. |
| 12/22/2028 | Expiration date for stock options with exercise prices $12.27 and $6.47. |
| 08/30/2029 | Expiration date for stock option with exercise price $7.53. |
| 12/20/2029 | Expiration date for stock option with exercise price $7.28. |
| 01/21/2030 | Expiration date for stock option with exercise price $8.08. |
Recommendation
buyThe significant open market purchases by the Chairman and Co-CEO, David Portnoy, signal strong conviction in Cryo-Cell International's future value. Insider buying, particularly from a top executive with extensive knowledge of the company, is often interpreted as a bullish indicator, suggesting the stock may be undervalued or that positive developments are anticipated. This action aligns management's interests directly with shareholders and warrants a 'buy' recommendation for investors looking for companies with strong insider confidence.
Keywords
Cryo-Cell International, CCEL, David Portnoy, Insider Buying, Stock Purchase, Form 4, Beneficial Ownership, Executive Stock Acquisition, Stem Cell Banking
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.